Nos publications

Impact of Granulation Solvent on Release Performance of Dual Matrix Extended-Release Tablets of Highly Water Soluble Drugs Formulated using Compritol® 888 ATO and Methocel® as Release Retarding Agents

  • Poster

AAPS PharmSci360 – Boston (USA)  - oct 2022

Ketkee Deshmukh, Swarnadeep Banerjee, Agnivesh Shrivastava, Sunil Bambarkar

The purpose of this study is to evaluate the impact of different granulation solvents on the performance of dual extended- release matrix tablets, formulated using a combination of Compritol® 888 ATO and Methocel® K100M, with two model APIs:

- highly water-soluble high dose (1000 mg) Metformin Hydrochloride

- freely water-soluble low dose (95 mg) Metoprolol Succinate

Télécharger (.pdf - 2.34 Mo)

Exploring the Potential of Compritol® 888 ATO for Abuse Deterrent Sustained Release Tablets

  • Poster

CRS Annual Meeting – Montreal (Canada)  - jui 2022

Agnivesh Shrivastava ; Renuka Tiwari ; Ketkee Deshmukh and Sunil Bambarkar

Télécharger (.pdf - 853.87 Ko)

Oral Drug Delivery for Modified Release Formulations

  • ebook

Wiley Library - Editors: Edmund S. Kostewicz, Maria Vertzoni, Heather A. E. Benson, Michael S. Roberts - avr 2022

Yvonne Rosiaux, Vincent Jannin and Cécile Morin

In this eBook, Gattefossé describes the strategies for MR formulation development with Lipids (Part II - chapter 11)